Pfizer and biontech announce submission of initial data to u.s. fda to support booster dose of covid-19 vaccine

New york, usa and mainz, germany, august 16, 2021 — pfizer inc. (nyse: pfe) and biontech se (nasdaq: bntx) today announced that they have submitted phase 1 data to the u.s. food and drug administration (fda) to support the evaluation of a third, or booster dose of the companies' covid-19 vaccine (bnt162b2) for future licensure. these data also will be submitted to the european medicines agency (ema) and other regulatory authorities in the coming weeks.
BNTX Ratings Summary
BNTX Quant Ranking